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Background: With the introduction of transcatheter aortic valve implantation, balloon aortic valvuloplasty (BAV) has experienced a revival for 
treatment of patients (pts) with severe aortic stenosis (AS). We aimed to determine the success, complications, and survival of pts after BAV.
Methods: A cohort of 219 pts with severe AS underwent 241 BAV procedures from 2006-2009. Of these, 16 pts (7.3%) had ≥2 BAV procedures. 
Clinical, hemodynamic, and follow up mortality data were collected.
Results: The mean age was 81.1±9.6 years, mean STS and logistic EuroSCORE were 13.4±7.6 and 43.3±23.6, respectively. In 78 pts (35.6%) the 
aortic valve area (AVA) increased to >1 cm2 and in 89 (40.6%) AVA increased to >0.4 cm2. The mean increase in AVA was 0.38±0.2 cm2 higher 
compared to the group who had redo of BAV with a mean increase of 0.26±0.2 cm2 , p=0.01. The mortality rate was 97 (44.2%) during median 
follow of 183 [60-456] days. Both final AVA and delta increase AVA were associated with lower mortality (OR 0.2 P=0.02 and OR 0.1 p=0.01, 
respectively). The mortality of pts with final AVA >1 cm2 vs. <1 cm2 (35.5 vs. 52.7%, p=0.03), and in pts with increase AVA >0.4 cm2 vs. <0.4 cm2 
(41.1 vs. 51%, p=0.2). Renal failure and NYHA class were significantly associated with mortality. 30 pts (13.6%) required blood transfusion.
Conclusion: Long-term survival after BAV is dismal. Efforts should be targeted to obtain (AVA >1 cm2 ) post-BAV to improve the survival rate. Aortic 
valve replacement should be pursued aggressively if this target is not met. 
219 patients underwent balloon aortic vavuloplasty
Pre-balloon valvuloplasty Post-balloon valvuloplasty P
Mean aortic valve area (cm2) 0.56±0.17 0.95±0.29 <0.001
Mean gradients (mmHg) 46.9±20.7 21.3±12.7 <0.001
Cardiac output (l/min) 3.9±1.8 4.1±1.3 0.7
Pulmonary pressure (mmHg) 51.2±17.3 49.1±16.6 0.001
Hematocrit (%) 35.4±4.6 29.3±5.2 <0.001
Creatinine (mg/dl) 1.4±1.0 1.9± 0.02
Troponin (ng/dl) 0.7±6.2 1.3±2.4 0.3
Serious adverse events 39 (17.8%)
Intraprocedural death 4 (1.8%)
Stroke 6 (2.7%)
Vascular complication 13 (5.9%)
Life threatening bleeding 6 (2.7%)
Moderate/Severe aortic regurgitation 3 (1.3%)
Profound hypotension requiring resuscitation and intubation 3 (1.3%)
Tamponade 1 (0.45%)
Left main occlusion 1 (0.45%)
Ventricular tachycardia 2 (0.9%)
